Clinical Data expands PGxHealth's FAMILION tests to include two new tests to diagnose heart diseases

Clinical Data, Inc. (NASDAQ: CLDA), announced today that its PGxHealth^® division is expanding its FAMILION family of genetic tests to include two new tests to diagnose heart diseases. With the launch of a test for Conduction Disease associated with Dilated Cardiomyopathy (CD-DCM) and a test for Short QT Syndrome, PGxHealth continues to lead the industry with the most comprehensive menu of genetic tests to diagnose or confirm familial heart diseases. The Company also announced the introduction of a significantly enhanced Brugada Syndrome (BrS) test, which now includes seven BrS-causative genes. In addition to these new test offerings, PGxHealth's FAMILION tests will be featured in several scientific presentations at the annual Heart Rhythm Society meeting. By expanding and enhancing the FAMILION family of tests, PGxHealth continues to help guide treatment that may prevent possible sudden cardiac death.

“Conduction abnormalities are often one of the first symptoms associated with Dilated Cardiomyopathy, frequently appearing years before the emergence of typical DCM symptoms”

"Conduction abnormalities are often one of the first symptoms associated with Dilated Cardiomyopathy, frequently appearing years before the emergence of typical DCM symptoms," said John Jefferies, M.D., M.P.H., Director, Cardiomyopathy and Heart Failure, Baylor Heart Center. "Early identification of patients with genetic DCM can lead to more timely interventions for both patients and their affected family members."

PGxHealth scientists and their academic collaborators are delivering three scientific presentations on related heart diseases at the Heart Rhythm Society meeting, including:

• Intronic and Exonic Splice Variants in KCNQ1's Exon 8 as a Pathogenic Substrate for Type 1 Long QT Syndrome. Abstract # PO2-77
• Distinguishing Arrhythmogenic Right Ventricular Cardiomyopathy-associated Mutations from Background Genetic Noise. Abstract # PO3-05
• Analysis of Species Conservation to Enhance Mutation Classification in Long QT Syndrome. Abstract # PO5-06

"These important presentations, together with our new FAMILION test offerings, highlight our commitment to working with academicians and leading healthcare providers to advance the science of genetic heart diseases," said Benjamin Salisbury, Ph.D., Vice President of Clinical Genetics at PGxHealth. "The Heart Rhythm meeting is well known for attracting the industry's leading heart disease experts and decision makers, and we are pleased to be able to bring new compelling data to this audience year after year."